[HTML][HTML] Chromosome 1q21 abnormalities in multiple myeloma
Abstract Gain of chromosome 1q (+ 1q) is one of the most common recurrent cytogenetic
abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly …
abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly …
[HTML][HTML] Multiple myeloma with high-risk cytogenetics and its treatment approach
I Hanamura - International Journal of Hematology, 2022 - Springer
Despite substantial advances in anti-myeloma treatments, early recurrence and death
remain an issue in certain subpopulations. Cytogenetic abnormalities (CAs) are the most …
remain an issue in certain subpopulations. Cytogenetic abnormalities (CAs) are the most …
Triplet therapy, transplantation, and maintenance until progression in myeloma
PG Richardson, SJ Jacobus, EA Weller… - … England Journal of …, 2022 - Mass Medical Soc
Background In patients with newly diagnosed multiple myeloma, the effect of adding
autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib …
autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib …
Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT …
MA Dimopoulos, D Dytfeld, S Grosicki… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE In the phase II ELOQUENT-3 trial (ClinicalTrials. gov identifier: NCT02654132),
elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved …
elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved …
Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk …
MF Kaiser, A Hall, K Walker, A Sherborne… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE The multicenter OPTIMUM (MUKnine) phase II trial investigated daratumumab,
low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd) …
low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd) …
[HTML][HTML] Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG …
LB Leypoldt, B Besemer, AM Asemissen, M Hänel… - Leukemia, 2022 - nature.com
The continuous implementation of novel agents in the treatment of multiple myeloma (MM)
has led to significant improvement in survival. Especially the addition of monoclonal …
has led to significant improvement in survival. Especially the addition of monoclonal …
Antibodies and bispecifics for multiple myeloma: effective effector therapy
C Cipkar, C Chen, S Trudel - Hematology, 2022 - ashpublications.org
The therapeutic landscape in multiple myeloma (MM) has changed dramatically over the last
2 decades. With the introduction of novel immunotherapies, patients with MM can expect …
2 decades. With the introduction of novel immunotherapies, patients with MM can expect …
How I treat high-risk multiple myeloma
Survival of multiple myeloma (MM) has significantly improved over the past decade;
however, a composed group of patients (15% to 20%), named high-risk (HR) MM, still …
however, a composed group of patients (15% to 20%), named high-risk (HR) MM, still …
[HTML][HTML] Targeted immunotherapy: harnessing the immune system to battle multiple myeloma
L Xu, C Wen, J Xia, H Zhang, Y Liang, X Xu - Cell Death Discovery, 2024 - nature.com
Multiple myeloma (MM) remains an incurable hematological malignancy disease
characterized by the progressive dysfunction of the patient's immune system. In this context …
characterized by the progressive dysfunction of the patient's immune system. In this context …
[HTML][HTML] Plasma cell leukemia: a review of the molecular classification, diagnosis, and evidenced-based treatment
Plasma cell leukemia is a rare and aggressive plasma cell dyscrasia associated with dismal
outcomes. It may arise de novo, primary plasma cell leukemia, or evolve from an antecedent …
outcomes. It may arise de novo, primary plasma cell leukemia, or evolve from an antecedent …